net dbt
valu prop rest lofti pipelin target
digest merit deal focu pipelin deliveri
follow yesterday announc bristol-my squibb acquir celgen
corp celg publish pro forma exhibit forecast
combin busi use bofaml biotech analyst ying huang celg
forecast base earlier feedback investor respons deal appear mainli
neg rang skeptic around revenu potenti celg pipelin concern
deal may intend mask headwind bmi key immuno-oncolog busi
base pf analysi estim ep accret ramp year
drop upon revlimid loss exclus loe
forecast celg stand-alon ebit peak bottom
assum bp declin pf om upon full revlimid generic valu
creation appear limit depend realiz pipelin revenu drive
upsid dcf basi seem lofti us maintain neutral rate
detail plan acquisit
flag detail transact deal financ equiti
cash celg holder own newco deal expect
close intend execut acceler share repurchas
buy back portion equiti issu transact op cost synergi
expect achiev third year post-deal close
pro forma forecast celg peak sale declin
driven key patent expiri exhibit model assum new
product pipelin revenu includ meaning contribut luspatercept md
liso-cel dlbcl ozanimod ms lag celg manag
aspir target nomin peak project late-stag product set
launch current stand-alone forecast includ contribut two
three product subject cvr conting valu right ozanimod liso-cel
car-t multipl myeloma potenti approv date lead indic
time-frame could potenti trigger cvr valu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop licens market
drug cardiovascular virolog oncolog
affect disord immunolog metabol
indic
rate neutral due premium multipl
limit catalyst think earli pipelin
offer meaning upsid opportun
requir valid assign
liso-cel car-t dlbcl heme
ozanimod uc ms
bofa merril lynch global research biotech team forecast us pharma team forecast
sale
amort intang
net sale
estimate synergi syn
celg synergi
celg synergi
tax opex synergi ex
new share issu celg holder
celg financi result bofa merril lynch global research estim note stand-alone ep number tabl differ establish number factor
acceler share buy-back stand-alone
exhibit forma summari dcf
synergi combin opex
synergi celg opex
accret
net incom celg
accret
present valu cash net incom
bofa merril lynch global research biotech team forecast us pharma team forecast
po base blend averag risk-adjust discount cash
flow dcf price-to-earnings multipl believ dcf base reason
assumpt compris minim contribut new opdivo/yervoy indic
valid late-stag clinic studi eliqui continu grow
prefer novel oral anticoagul dcf assum wacc
termin growth rate price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
downsid risk po unimpress data lung cancer studi neg
result rel earli stage io pipelin slower-than-anticip
growth eliqui
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
